CORDIS
EU research results

CORDIS

English EN
Novel testing strategies for in vitro assessment of allergens

Novel testing strategies for in vitro assessment of allergens

Objective

Allergies to sensitising agents are steadily increasing. Risk assessment for potential skin- or lung-sensitisers, completely depends on animal testing. The overall objective of Sens-it-iv is to produce in vitro alternatives for these assays, and develop them upto the level of pre-validation. Besides reducing animal experimentation, an increase the accuracy of predicting sensitising potencies is expected. In vitro mechanisms, relevant for in vivo sensitisation, will be identified at the level of human lung or skin epithelial cells (EC), dendritic cells (DC) and T-cells.

These efforts imply specific scientific (S) and technologic (T) objectives:
a. Existing data on sensitising, irritating and toxic compounds are collected (S).
b. In vivo changes induced by selected compounds in the specified cell types are described using functional genomics (S).
c. Similarly, the impact of compounds on individual cells, and the interaction between these cells is assessed in vitro (S).
d. The physico-chemical properties of chemicals responsible for metabolic activation and hapten-formation are determined (S).
e. The data are collected in an Inductive Database allowing queries for data patterns and predictive models (T).
f. Mechanisms specifically involved in skin and respiratory sensitisation are identified using bio-informatics (S).
g. The information is used to adapt/improve existing techniques, and to develop organotypic models derived from human cells assays (T).
h. A proof of principle is established on a set of selected skin and respiratory sensitisers, irritants and toxic compounds (T).

Sens-it-iv is innovative primarily by the coordinated and extensive characterisation of the impact of compounds on cell-cell interactions for identification of the key mechanisms of sensitisation. Consistency with existing and ongoing projects, and optimal exploitation of these achievements is ensured by the involvement of ECVAM, COLIPA, ECOPA, IVTIP and OECD in various levels of the project.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

NOVOZYMES SA

Address

Krogshoejvej 36
Bagsvaerd

Denmark

Administrative Contact

Erwin ROGGEN (Dr)

Participants (28)

Sort alphabetically

Expand all

JOINT RESEARCH CENTRE (EUROPEAN COMMISSION DG JRC). ACRONYM: COM.IHC

Belgium

SYNGENTA AG

United Kingdom

UNILEVER UK CENTRAL RESOURCES LIMITED

United Kingdom

LUNDS UNIVERSITET

Sweden

INSTITUTE FOR RESEARCH IN BIOMEDICINE

Switzerland

VU UNIVERSITY MEDICAL CENTRE

Netherlands

THE UNIVERSITY OF LIVERPOOL

United Kingdom

UNIVERSITY OF THE WEST OF ENGLAND, BRISTOL

United Kingdom

VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK

Belgium

MILTENYI BIOTEC GMBH

Germany

PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI DELL'IMMACOLATA CONCEZIONE, ISTITUTO DERMOPATICO DELL'IMMACOLATA, IRCCS

Italy

COSMITAL SA (FULLY OWNED SUBSIDIARY OF WELLA SERVICE GMBH, DARMSTADT, GERMANY)

Switzerland

IN VITRO TESTING INDUSTRIAL PLATFORM

Spain

HELMA HERMANS (SCIENTIFIC WRITING & CONSULTANCY S.C.)

Spain

PROTEOMIKA S.L.

Spain

VRIJE UNIVERSITEIT BRUSSEL

Belgium

PROTEOME SCIENCES PLC

United Kingdom

PROTEOME SCIENCES R&D GMBH & CO. KG

Germany

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG FREIBURG CENTER FOR DATA ANALYSIS AND MODELLING

Germany

COMITÉ DE LIAISON EUROPÉEN DE L'INDUSTRIE DE LA PARFUMERIE, DES PRODUITS COSMÉTIQUES ET DE TOILETTE

Belgium

FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

L'ORÉAL

France

MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., REPRESENTED BY THE MAX-PLANCK-INSTITUT FÜR IMMUNBIOLOGIE

Germany

RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE AACHEN

Germany

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

UNIVERSITÀ DEGLI STUDI DI MILANO

Italy

UNIVERSITÀ DI FIRENZE

Italy

UNIVERSITÉ DE STRASBOURG

France

Project information

Grant agreement ID: 18681

  • Start date

    1 October 2005

  • End date

    31 March 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 14 486 665

  • EU contribution

    € 10 999 700

Coordinated by:

NOVOZYMES SA

Denmark